Teva Pharmaceutical Industries (TEVA) Gross Margin (2009 - 2026)
Teva Pharmaceutical Industries (TEVA) posted quarterly Gross Margin of 49.52% for Q1 2026, up 128.0% year-on-year from 21.72% in Q1 2025, and down 12.16% on a QoQ basis from 56.38% in Q4 2025.
Teva Pharmaceutical Industries (TEVA) Gross Margin (2009 - 2026) Analysis & Trends
Teva Pharmaceutical Industries (TEVA) has reported Gross Margin for 18 consecutive years, with 49.52% the latest figure, recorded in Q1 2026.
- Quarterly Gross Margin rose 128.0% year-over-year to 49.52% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 52.07% (down 137.0% YoY) and the FY2025 annual result came in at 51.79%, up 305.0% from the prior year.
- Gross Margin slipped to 49.52% in Q1 2026 per TEVA's latest filing, from 56.38% in the prior quarter.
- Over the last five years, Gross Margin for TEVA reached as high as 73.14% in Q4 2024 and fell as low as 43.21% in Q1 2023.
- A 5-year average of 50.14% and a median of 48.24% in 2025 frame the typical range for Gross Margin.
- Annual changes were most pronounced in 2024 — Gross Margin surged 1893 bps — and 2025, when it plunged 1676 bps.
- Year by year, Gross Margin stood at 45.57% in 2022, then increased by 19 bps to 54.21% in 2023, then soared by 35 bps to 73.14% in 2024, then retreated by 23 bps to 56.38% in 2025, then declined by 12 bps to 49.52% in 2026.
- According to Business Quant data, Gross Margin over the past three periods registered 49.52%, 56.38%, and 51.43% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 49.52% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 71.66% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 62.93% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 82.93% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 32.97% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 98.31% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 57.26% |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | 55.84% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 49.52% |
| Dec 31, 2025 | 56.38% |
| Sep 30, 2025 | 51.43% |
| Jun 30, 2025 | 50.34% |
| Mar 31, 2025 | 48.24% |
| Dec 31, 2024 | 73.14% |
| Sep 30, 2024 | 49.58% |
| Jun 30, 2024 | 48.61% |
| Mar 31, 2024 | 46.37% |
| Dec 31, 2023 | 54.21% |
| Sep 30, 2023 | 48.08% |
| Jun 30, 2023 | 46.31% |
| Mar 31, 2023 | 43.21% |
| Dec 31, 2022 | 45.57% |
| Sep 30, 2022 | 46.43% |
| Jun 30, 2022 | 47.39% |
| Mar 31, 2022 | 47.53% |
| Dec 31, 2021 | 50.00% |
| Sep 30, 2021 | 46.15% |
| Jun 30, 2021 | 47.90% |